X0202 SCHEDULE 13G 0000919185 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/31/2026 0001847345 Aspire Biopharma Holdings, Inc. 738920206 194 Candelaro Drive, #233 Humacao PR 00791 Rule 13d-1(b) Highbridge Capital Management, LLC DE 273000.00 0.00 273000.00 0.00 273000.00 N 5.2 IA OO Reflects shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants. Aspire Biopharma Holdings, Inc. 194 Candelaro Drive, #233, Humacao, Puerto Rico 00791 This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the common stock, par value $0.0001 per share ("Common Stock") of Aspire Biopharma Holdings Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds; The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017. Highbridge is a Delaware limited liability company. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,024,124 shares of Common Stock outstanding as of March 27, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026, and assumes the exercise of the warrants held by Highbridge Funds. 5.2% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Highbridge Capital Management, LLC /s/ Kirk Rule 05/15/2026